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Abstract
Opiate drugs are the most effective analgesics available but their clinical use is restricted by severe side effects.
Some of these undesired actions appear after repeated administration and are related to adaptive changes
directed at counteracting the consequences of sustained opioid receptor activation. Here we will discuss
adaptations that contribute to the development of tolerance. The focus of the first part of the review is set on
molecular mechanisms involved in the regulation of opioid receptor signalling in heterologous expression systems
and neurons. In the second part we assess how adaptations that take place in vivo may contribute to analgesic
tolerance developed during repeated opioid administration.
I. Introduction
Opiates are among the most effective analgesics known
but their clinical use is limited by severe side effects.
Some of these undesired actions including tolerance,
dependence and abuse usually appear after repeated
opioid administration, and have been linked to adapta-
tions that take place in order to counteract prolonged
opioid receptor activation [1,2]. Adaptive changes have
been described at different organizational levels within
the central nervous system, ranging from receptor and
cellular alterations to functional modifications of differ-
ent neuronal networks [3,4]. Regulation that occurs at
the receptor level results in the progressive waning of
signalling efficacy and is known as desensitization.
Mechanisms of opioid receptor desensitization were
initially characterized in immortalized cell lines [5] but
more recent studies have extended observations to cul-
tured neurons [6-8] and animal models [9-12]. Here we
will review these findings with special focus on recent
efforts to understand how regulation of receptor signal-
ling may contribute to analgesic tolerance developed
during repeated opioid administration.
II. Opioid receptor regulation in heterologous
expression systems
Opioid receptor desensitization and endocytosis
Studies in immortalized cell lines have shown that like
for many other G protein-coupled receptors (GPCRs),
opioid receptor activation involves a series of confor-
mational changes [13,14] that trigger signalling and
regulation. Regulatory steps usually start with phos-
phorylation of the receptor [15,16] followed by barres-
tin recruitment [17,18] and disruption of receptor
signaling via G-protein coupled effectors [19,20]. In
addition, since arrestins bind to the coat structure of
clathrin-coated pits [21,22] a great majority of ligands
that promote functional desensitization also enhance
sequestration. The frequent association of these two
processes was initially taken as an indication that
opioid receptor internalization and desensitization
were causally linked [23,24], an interpretation that was
reinforced by studies showing that morphine failed to
induce both, internalization [25,26] and desensitization
[27,28]. Moreover, given that morphine induces more
analgesic tolerance than agonists capable of triggering
a full regulatory response [29-31], its high potential
for tolerance was initially considered as the conse-
quence of cellular adaptations to counteract sustained
signaling by receptors that were unable to desensitize
or internalize [23,25,27]. However, morphine’sf a i l u r e
to trigger regulation of receptor signaling cannot be
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shown that this drug causes barrestine recruitment,
desensitization and endocytosis of mu (MORs) [32-35]
and delta (DORs) [35,36] opioid receptors. Moreover,
animal studies have confirmed that receptor regulation
is essential for morphine tolerance to develop since
transgenic mice lacking barrestin2 display enhanced,
longer lasting analgesic responses to the drug [37,38].
Based on these observations, the mechanism of mor-
phine tolerance was reconsidered and the contribution
of endocytosis re-evaluated. This alternative hypothesis
proposes barrestin-driven receptor-G protein uncou-
pling (desensitization) as the mechanism responsible
for the loss of morphine’s analgesic action, which is
in turn exacerbated by receptor failure to internalize
and undergo resensitization [38,39]. However, this
mechanism cannot be generalized to agonists that
induce internalization or even to other opioid ligands
that like morphine fail to do so. In particular, homo-
logous desensitization does not account for tolerance
induced by AR-M1000390, a low internalizing DOR
agonist [40] whose repeated administration induces
tolerance without modifying receptor ability to
activate the G protein [12]. Moreover, internalization
per se warrants neither resensitization nor absence of
tolerance. For example although SNC-80 produces
rapid internalization of DORs [41], its systemic adminis-
tration induces long lasting analgesic tolerance after a sin-
gle administration [11]. MOR activation by efficiently
internalizing ligands is also associated with progressive
loss of analgesic efficacy, although unlike SNC-80, MOR
agonists require repeated administration for tolerance to
develop [42].
Post-endocytic sorting of opioid receptors
Functional consequences of receptor internalization
cannot be fully understood without considering what
happens after sequestration. Hence, if internalization is
associated to receptor recycling, the process allows to
restore functional receptors to the membrane [43,44].
Both MORs [39] and DORs [41,45,46] have been shown
to undergo recycling that contributes to their functional
resensitization. In contrast, if the receptor is preferen-
tially directed towards the lysosomal compartment,
internalization leads to prolonged desensitization due to
its proteolytic degradation [47,48].
Factors responsible for sorting opioid receptors to
these alternative pathways are multiple, and some are
specific to each receptor subtype. An important deter-
minant of lysosomal sorting is ubiquitination [49] and
both DORs and MORs have been shown to become
ubiquitinated and degraded after stimulation. However,
while DORs are ubiquitinated within minutes of activa-
tion [48,50] MORs require various hours of stimulation
[51]. On the other hand, despite their rapid ubiquitina-
tion, DORs are not immediately degraded but may
remain withheld in the endosomal compartment [52]
for periods that may last as long as four hours of ago-
nist exposure [11,53]. The discrepancy in the time
required to undergo ubiquitination and degradation is
consistent with the fact that DOR sorting towards the
degradation path is not dependent upon ubiquitin
addition [48,54]. Instead, their trafficking to the late
endosomal compartment relies, at least in part, upon
interaction with sorting proteins of the GASP (G pro-
tein coupled receptor associated sorting protein) family
[47,54,55]. MORs also bind GASPs, but the low affinity
of this interaction seems to account for their lower
tendency to undergo lysosomal targeting and degrada-
tion as compared to DORs [47,55]. In addition, a pri-
mary sequence within the C-terminal domain of some
MOR isoforms facilitates their active targeting towards
the recycling pathway [56]. Yet this is not the only
determinant of MOR recycling since isoforms lacking
the sorting sequence may also be sent back to the
membrane after internalization [57,58]. Indeed, MORs
are also known to constitutively interact with neuronal
membrane glycoprotein M6a, which accelerates their
recycling after internaliza t i o n[ 5 9 ] .I na d d i t i o n ,M O R
and DOR recycling may be dynamically regulated
through receptor phosphorylation [46,60] and interac-
tions with barrestin1 and barrestin2 [61]. See Figure 1
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Figure 1 Steps involved in the homologous desensitization of
GPCRs. According to the classical model of homologous
desensitization, receptor activation by an agonist induces a series of
conformational changes that trigger receptor signalling and
regulation. The first of these regulatory steps is receptor
phosphorylation by GRK (1). Once phosphorylated receptor affinity
for barrestin increases, enhancing interaction between the two
proteins (2) and promoting internalization (3). Internalized receptors
are then directed to early/sorting endodomes where interaction
with different regulatory proteins will allow them to recycle back to
the membrane (4) or will directed towards degradation (5).
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logous desensitization.
III. Regulation of opioid-mediated
responses in neurons
Studies in slices and neuronal cultures have confirmed
that neuronal MORs may undergo barrestin-dependent
internalization by full agonists like DAMGO and par-
tial agonists like morphine [6]. Importantly, internali-
zation following short term exposure to morphine
varies across different neuronal populations. In parti-
cular, while this drug induced MOR endocytosis in
striatal neurons [6] it was without effect in those of
the locus coeruleus (LC) [7,62], dorsal root ganglion
(DRG) [8] or enteric plexus [63,64]. Such differences
are not surprising since as a partial agonist internaliza-
tion by morphine is expected to be influenced by the
level and type of endocytic proteins expressed in each
neuronal subtype. In keeping with this interpretation
prolonged morphine exposure was found to enhance
dynamin expression in enteric neurons, turning the
agonist into an internalizing ligand [64].
Functional assays have revealed that receptor stimu-
lation by morphine and by more efficacious ligands are
all capable of inducing functional desensitization of
MOR-mediated neural responses. However, the rela-
tionship between internalization and loss of signaling
capacity seemed influenced by the cell type and
effector considered. In particular, although short-term
(20-30 min) exposure of DRG and LC neurons to
internalizing ligands was associated with desensitiza-
tion of channel-mediated responses, sequestration was
not necessary for desensitization to take place [7,62].
On the other hand, interfering with sequestration of
striatal MORs resulted in partial reduction of the
desensitization of cyclase responses evoked by
DAMGO and morphine [65]. Apart from distinct need
for internalization, the mechanistic basis of desensitiza-
tion seems also effector specific. In particular, N-type
Ca
+2 channels in DRG neurons were shown to undergo
rapid desensitization that was not affected by
barrestin2 knockout [66] but was instead mediated by
a heterologous mechanism acting downstream of the
receptor [8,67,68]. In contrast, desensitization of G
protein activated inward rectifier K+ (GIRK) channels
in LC neurons was homologous [62], and dependent
on the combined activity of ERK1/2, G protein
receptor kinase 2 (GRK2) and arrestin2 [68]. barrestin2
was also involved in the desensitization of cyclase
responses following sustained exposure of striatal
MORs to morphine and DAMGO [65]. However, in
spite of its ability to trigger MOR regulation, exposure
to morphine induced superactivation of the
striatal cAMP cascade [69], suggesting that MOR
desensitization when associated to this effector might
not be enough to completely avoid cellular compensa-
tory mechanisms.
Information concerning post-endocytic sorting of
neuronal opioid receptors is quite limited. Studies in
DRG neurons indicate that MORs undergo constitu-
tive recycling which requires barrestin2-dependent
internalization and trafficking through a monensin
sensitive compartment [8,66]. Agonist stimulation of
these receptors induces their colocalization with Rab4
and Rab11, indicating redistribution of DRG MORs to
recycling endosomes [8]. Functional consequences of
receptor recycling have been assessed in LC neurons.
In these cells MOR desensitization by the endogenous
agonist Met-enkephalin could be reversed upon
agonist removal, resulting in complete recovery of
receptor ability to evoke GIRK channel activation
[7,70]. Interestingly, the mechanism involved in resen-
sitization was different depending on whether desensi-
tization was accompanied or not by internalization.
Indeed, when recovery took place after internalization,
resensitization was sensitive to recycling disruption by
monensin [70]. In contrast, when internalization was
blocked, desensitization and recovery could both take
place at the membrane [7], pointing to the existence
of multiple, complementary mechanisms for achieving
similar regulatory control of opioid receptor signaling.
The existence of multiple, complementary and cell-
specific regulatory responses were not necessarily
anticipated from studies in heterologous systems.
They should nonetheless be carefully considered since
they may point to the impossibility of developing a
single, universal strategy for avoiding analgesic
tolerance.
IV. In vivo regulation of opioid receptor signaling
A critical question in understanding long term effects of
opioids is whether regulatory responses described in cel-
lular models are also triggered in vivo,a n di fs o ,w h a t
are their behavioral correlates. Insight into these issues
has been obtained by assessing regulatory responses
triggered by the release of endogenous opioids or fol-
lowing exogenous administration of different opioid
receptor agonists.
Opioid receptor regulation by release
of endogenous opioids
The release of endogenous opioid peptides during nox-
ious stimulation may produce phosphorylation [10,71]
and internalization [72,73] of central and peripheral
MORs. These regulatory responses were triggered by
stimuli that lead to development of persistent pain
syndromes [10,72,73] but not by acute noxious stimu-
lation [74], a difference that has been attributed to
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ter. Consistent with this interpretation, acute painful
stimuli may provoke MOR internalization if the stimu-
lation is accompanied by administration of peptidase
inhibitors that prevent rapid degradation of the
released opioids [75].
From a functional point of view MOR phosphoryla-
tion following sciatic nerve ligature was correlated
with desensitization of receptor ability to stimulate the
G protein, development of cyclase superactivation,
appearance of thermal hyperalgesia and reduced
analgesic response to exogenous opioids [10,76]. The
use of b-endorphin knock-out mice confirmed a causal
link between MOR phosphorylation by this peptide
and reduced responsiveness to exogenous ligands since
sciatic nerve ligature in knock-out animals failed to
produce both [10]. On the other hand, regulatory
mechanisms triggered by endogenous opioids during
the course of chronic inflammatory pain seem to have
a protective effect against morphine tolerance. Indeed,
depletion of opioids from white blood cells of rats that
had received an intra-plantar injection of complete
Freund’s adjuvant (CFA) prevented MOR sequestration
in primary afferents. Together with inhibition of
sequestration, opioid depletion was associated with the
exacerbation of cyclase superactivation and analgesic
tolerance produced by intraplantar administration of
morphine [72].
Opioid receptor regulation by administration
of opioid agonists
As mentioned in previous sections, studies character-
izing homologous desensitization of opioid receptors
have prompted two alternative hypotheses in order to
explain morphine tolerance. Although not necessarily
compatible at other levels, both conceptualizations
agree upon the fact that receptor internalization may
h a v eap r o t e c t i v ee f f e c ta g a i n s tt h el o s so fm o r p h i n e ’s
analgesic efficacy. This possibility has been directly
assessed by Kim et al, 2008 [77] who used a knock-in
mouse model in which wild-type MORs were replaced
with a mutant receptor capable of undergoing rapid
morphine-dependent sequestration [27]. What the
authors report is that a 5 day treatment which almost
abolished morphine analgesia in wild type mice pro-
duced no tolerance in knock-in animals [77]. The
idea that MOR internalization negatively influences
the development of tolerance is also supported by
experiments carried out in wild type animals where
the rate at which analgesic efficacy diminishes is fas-
ter for low internalizing opiates like morphine or her-
oin [38,77-79] than for efficiently internalizing
agonists like DAMGO [80], etorphine [38,81] or
methadone [38,77]. However, the protective effect of
internalization is limited, since treatments of 7 days
or longer will all eventually induce analgesic
tolerance [37,78,81,82] independent of the degree of
internalization triggered by the agonist. Although
part of this effect may be accounted for by adapta-
tions that take place at synaptic and network levels
[4], receptor adaptations are also involved since
tolerance is paralleled by receptor desensitization
[37,78,81-84] and down regulation [81,85]. Thus, if
the intent is to eventually harness opioid receptor
regulation as a means of prolonging opioid analgesia,
it will be necessary to look beyond internalization.
Characterization of the post-endocytic mechanisms
whereby in vivo sequestration provides transient pro-
tection from tolerance as well as a better understand-
ing of the causes leading to down-regulation and
delayed loss of analgesic efficacy, seem essential steps
for the rational development of novel, longer acting
opioid analgesics.
The relationship between endocytic trafficking and
analgesia is also being actively pursued for DORs. A
report by Pradhan et al, 2009 [11] has recently estab-
lished that a single injection of SNC-80 produced in
vivo internalization of DORs which was paralleled by
the development of acute analgesic tolerance. In
contrast, the administration of an equianalgesic dose
of AR-M1000390 produced neither internalization nor
modification of subsequent analgesic responses. Based
on these observations it would be tempting to specu-
late that acute tolerance to DOR agonists is deter-
mined by internalization. However, this interpretation
is ruled out by results obtained with deltorphin II,
w h o s ea d m i n i s t r a t i o ni sf r e eo fa c u t et o l e r a n c e[ 8 6 ]
despite its high internalization capacity [87]. The rea-
son for the distinct tolerance potential displayed by
SNC-80 and deltorphin II remains to be elucidated,
but analysis of post-endocytic trafficking could shed
some light onto the issue. Studies in immortalized
cell lines indicate that internalization by SNC-80 is
not followed by for receptor recycling [41] and in
vivo experiments show that four hours after its sys-
temic administration SNC-80-stimulated DORs
remain trapped in the cytosol while analgesic toler-
ance is maximal [11]. On the other hand, internaliza-
tion by deltorphin analogues is associated with partial
recycling and resensitization of DOR signalling [88],
both of which may contribute to a faster recovery of
analgesic efficacy upon repeated administration of
this type of ligands [86]. Based on these observations
it would be interesting to determine whether prefer-
ential sorting towards the recycling path is what
makes deltorphin II less prone to tolerance than
SNC-80. The molecular underpinnings of agonist-spe-
cific sorting could include stabilization of agonist-
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with sorting proteins such as GASPs or barrestins.
This reasoning is supported by reports indicating
that DORs may adopt multiple active conformations [14]
that are distinctively modulated by Src [89,90], which is
in turn involved in the modulation of DOR recycling
efficacy [46].
Comparison of long-term analgesic actions evoked by
internalizing and non-internalizing DOR agonists has
confirmed that similar to what was observed for
MORs, both types of ligands induce tolerance after
repeated administration [12,86]. Remarkably, for some
agonists desensitization of DOR-mediated signals takes
place at the receptor while for others desensitization
occurs at the level of the effector. For example, while
tolerance by SNC-80 involves receptor desensitization
AR-M1000390 leaves DORs unaffected but reduces Ca
+2 channel ability to respond to stimuli [12]. An addi-
tional level of diversity that has been described in the
regulation of DOR-mediated in vivo responses is that
different behaviours display distinct sensitivity to toler-
ance. For example, while repeated AR-M1000390
administration did not modify drug ability to induce
anxiolytic and psychomotor responses, it induced com-
plete analgesic tolerance [12]. It seems unlikely that
“response-specific” tolerance generated by AR-
M1000390’s is related to its failure to internalize DORs
since similar specificity has been described for interna-
lizing ligands. In effect, sustained treatment with SNC-
80 led to the progressive reduction of its pro-convul-
sive but not antidepressant actions [91]. Similarly, sus-
tained administration of deltorphin II resulted in the
progressive reduction of antinociceptive but not anti-
hyperalgesic actions induced by this drug [86]. The
fact that sustained stimulation of the same receptor
may result in different degrees of tolerance for distinct
behavioural responses is highly reminiscent of observa-
tions obtained in neuronal cultures where signalling
regulation was found to be cell- and effector-specific.
As previously mentioned, this multiplicity of regulatory
mechanisms argues against the possibility of develop-
ing a single universal means of controlling analgesic
tolerance. But, on the other hand, it could provide a
novel strategy for the development of more specific,
longer acting analgesics. Indeed, diversity could be an
advantage if it were to allow directing the pharmacolo-
gical stimuli towards those receptors that are specifi-
cally involved in analgesic responses and whose
cellular location and/or effector association would
make them more resistant to progressive waning of
signalling efficacy. In this sense it might be helpful to
think of receptors not as isolated membrane proteins
but as part of signalling complexes containing a
combination of G proteins [14,92], effectors [93], scaf-
folding [94] and/or regulatory proteins whose identity
is determined by the cell type and compartment in
which receptors are expressed [95]. Within complexes
formed in different cells, structural restrictions
imposed by distinct interaction partners may force
receptors and/or effectors into conformations which
need not be equally recognized by regulatory proteins
[5,96]. It would therefore be conceivable that develop-
ment of ligands capable of specifically activating signal-
ling complexes with the least capacity to trigger the
regulatory mechanisms underlying tolerance could
result in more prolonged analgesic actions than those
of currently available opioids. A schematic representa-
tion of this idea is shown in Figure 2.
V. Concluding remarks
Initial mechanistic hypotheses concerning the molecular
bases of opioid tolerance focused on homologous desen-
sitization, viewing internalization as a key protective
step for maintaining analgesic efficacy. Neuronal and in
vivo studies tend to partially confirm this view, but also
point to a greater level of complexity where post-endo-
cytic sorting and multiplicity of regulatory mechanisms
argue against a simple, universal strategy for reducing
tolerance. Embracing this diversity through the produc-
tion of biased ligands capable of favouring recycling or
of directing pharmacological stimuli towards signalling
complexes that are more resistant to functional desensi-
tization could constitute novel strategies for rational
design of longer acting opioid analgesics.
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Figure 2 Biased agonists targeting cell-specific receptor/effector complexes may prove a valid approach for developing longer acting
opioid analgesics. Conformational restrictions within receptor-effector complexes present in cell A make them more sensitive to the effect of
regulatory proteins than receptor-effector complexes in cell B. If these differences make analgesic responses mediated by cell A more prone to
tolerance than those mediated by cell B, a) agonists that preferentially recognize and activate complexes in cell B are expected to produce
longer lasting analgesia than b) an equally efficacious agonist that preferentially stimulates complexes in cell A or c) agonists that do not
discriminate among complexes.
Nagi and Piñeyro Molecular Brain 2011, 4:25
http://www.molecularbrain.com/content/4/1/25
Page 6 of 9Université de Montréal, Montréal, Québec, H3C 3J7, Canada.
3Centre de
recherche du CHU Sainte-Justine, 3175, Côte-Sainte-Catherine Montréal,
Québec, H3T 1C5, Canada.
Authors’ contributions
KN conducted reference research, contributed discussion and figure
concerning signalling complexes. GP conducted reference research and
wrote the review. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 March 2011 Accepted: 13 June 2011
Published: 13 June 2011
References
1. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG:
Desensitization of g protein-coupled receptors and neuronal functions.
Annu Rev Neurosci 2004, 27:107-144.
2. Martini L, Whistler JL: The role of mu opioid receptor desensitization and
endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol
2007, 17(5):556-564.
3. Ko SW, Wu LJ, Shum F, Quan J, Zhuo M: Cingulate nmda nr2b
receptors contribute to morphine-induced analgesic tolerance. Mol
Brain 2008, 1:2.
4. Christie MJ: Cellular neuroadaptations to chronic opioids: Tolerance,
withdrawal and addiction. Br J Pharmacol 2008, 154(2):384-396.
5. Pineyro G, Archer-Lahlou E: Ligand-specific receptor states: Implications
for opiate receptor signalling and regulation. Cell Signal 2007,
19(1):8-19.
6. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M: Morphine promotes
rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal
neurons. J Neurosci 2005, 25(34):7847-7857.
7. Arttamangkul S, Torrecilla M, Kobayashi K, Okano H, Williams JT: Separation
of mu-opioid receptor desensitization and internalization: Endogenous
receptors in primary neuronal cultures. J Neurosci 2006, 26(15):4118-4125.
8. Walwyn WM, Wei W, Xie CW, Chiu K, Kieffer BL, Evans CJ, Maidment NT: Mu
opioid receptor-effector coupling and trafficking in dorsal root ganglia
neurons. Neuroscience 2006, 142(2):493-503.
9. Trafton JA, Basbaum AI: [d-ala2, n-mephe4, gly-ol5]enkephalin-induced
internalization of the micro opioid receptor in the spinal cord of
morphine tolerant rats. Neuroscience 2004, 125(3):541-543.
10. Petraschka M, Li S, Gilbert TL, Westenbroek RE, Bruchas MR, Schreiber S,
Lowe J, Low MJ, Pintar JE, Chavkin C: The absence of endogenous beta-
endorphin selectively blocks phosphorylation and desensitization of mu
opioid receptors following partial sciatic nerve ligation. Neuroscience
2007, 146(4):1795-1807.
11. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A,
Massotte D, Gaveriaux-Ruff C, Kieffer BL: In vivo delta opioid receptor
internalization controls behavioral effects of agonists. PLoS One 2009,
4(5):e5425.
12. Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C,
Kieffer BL: Ligand-directed trafficking of the delta-opioid receptor in vivo:
Two paths toward analgesic tolerance. J Neurosci 2010,
30(49):16459-16468.
13. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, Devi LA:
Conformation state-sensitive antibodies to g-protein-coupled receptors.
J Biol Chem 2007, 282(8):5116-5124.
14. Audet N, Gales C, Archer-Lahlou E, Vallieres M, Schiller PW, Bouvier M,
Pineyro G: Bioluminescence resonance energy transfer assays reveal
ligand-specific conformational changes within preformed signaling
complexes containing delta-opioid receptors and heterotrimeric g
proteins. J Biol Chem 2008, 283(22):15078-15088.
15. Kovoor A, Celver JP, Wu A, Chavkin C: Agonist induced homologous
desensitization of mu-opioid receptors mediated by g protein-coupled
receptor kinases is dependent on agonist efficacy. Mol Pharmacol 1998,
54(4):704-711.
16. Marie N, Aguila B, Hasbi A, Davis A, Jauzac P, Allouche S: Different kinases
desensitize the human delta-opioid receptor (hdop-r) in the
neuroblastoma cell line sk-n-be upon peptidic and alkaloid agonists. Cell
Signal 2008, 20(6):1209-1220.
17. Zhang X, Wang F, Chen X, Li J, Xiang B, Zhang YQ, Li BM, Ma L: Beta-
arrestin1 and beta-arrestin2 are differentially required for
phosphorylation-dependent and -independent internalization of delta-
opioid receptors. J Neurochem 2005, 95(1):169-178.
18. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE,
Bohn LM: An opioid agonist that does not induce micro-opioid receptor-
arrestin interactions or receptor internalization. Mol Pharmacol 2007,
71(2):549-557.
19. Qiu Y, Loh HH, Law PY: Phosphorylation of the delta-opioid receptor
regulates its beta-arrestins selectivity and subsequent receptor
internalization and adenylyl cyclase desensitization. J Biol Chem 2007,
282(31):22315-22323.
20. Celver JP, Lowe J, Kovoor A, Gurevich VV, Chavkin C: Threonine 180 is
required for g-protein-coupled receptor kinase 3- and beta-arrestin
2-mediated desensitization of the mu-opioid receptor in xenopus
oocytes. JB i o lC h e m2001, 276(7):4894-4900.
21. Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG: The interaction of
beta-arrestin with the ap-2 adaptor is required for the clustering of beta
2-adrenergic receptor into clathrin-coated pits. J Biol Chem 2000,
275(30):23120-23126.
22. Laporte SA, Miller WE, Kim KM, Caron MG: Beta-arrestin/ap-2 interaction in
g protein-coupled receptor internalization: Identification of a beta-
arrestin binging site in beta 2-adaptin. J Biol Chem 2002,
277(11):9247-9254.
23. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M: Functional
dissociation of mu opioid receptor signaling and endocytosis:
Implications for the biology of opiate tolerance and addiction. Neuron
1999, 23(4):737-746.
24. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M,
Grandy DK, Williams JT: Mu-opioid receptors: Ligand-dependent
activation of potassium conductance, desensitization, and
internalization. J Neurosci 2002, 22(13):5769-5776.
25. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, von
Zastrow M: Morphine activates opioid receptors without causing their
rapid internalization. J Biol Chem 1996, 271(32):19021-19024.
26. Aguila B, Coulbault L, Boulouard M, Leveille F, Davis A, Toth G, Borsodi A,
Balboni G, Salvadori S, Jauzac P, Allouche S: In vitro and in vivo
pharmacological profile of ufp-512, a novel selective delta-opioid
receptor agonist; correlations between desensitization and tolerance. Br
J Pharmacol 2007, 152(8):1312-1324.
27. Finn AK, Whistler JL: Endocytosis of the mu opioid receptor reduces
tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001,
32(5):829-839.
28. Eisinger DA, Ammer H, Schulz R: Chronic morphine treatment inhibits
opioid receptor desensitization and internalization. J Neurosci 2002,
22(23):10192-10200.
29. Connor M, Osborne PB, Christie MJ: Mu-opioid receptor desensitization: Is
morphine different? Br J Pharmacol 2004, 143(6):685-696.
30. Grecksch G, Bartzsch K, Widera A, Becker A, Hollt V, Koch T: Development
of tolerance and sensitization to different opioid agonists in rats.
Psychopharmacology (Berl) 2006, 186(2):177-184.
31. Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC: Opioid
agonist efficacy predicts the magnitude of tolerance and the regulation
of mu-opioid receptors and dynamin-2. Eur J Pharmacol 2007, 563(1-
3):92-101.
32. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ: Opioid
agonists have different efficacy profiles for g protein activation, rapid
desensitization, and endocytosis of mu-opioid receptors. J Biol Chem
2003, 278(21):18776-18784.
33. Dang VC, Williams JT: Morphine-induced mu-opioid receptor
desensitization. Mol Pharmacol 2005, 68(4):1127-1132.
34. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C,
Dewey WL, Bailey CP, Rosethorne EM, Charlton SJ, Henderson G, et al: Mu-
opioid receptors: Correlation of agonist efficacy for signalling with
ability to activate internalization. Mol Pharmacol 2010, 78(4):756-766.
35. Molinari P, Vezzi V, Sbraccia M, Gro C, Riitano D, Ambrosio C, Casella I,
Costa T: Morphine-like opiates selectively antagonize receptor-arrestin
interactions. J Biol Chem 2010, 285(17):12522-12535.
36. Navratilova E, Eaton MC, Stropova D, Varga EV, Vanderah TW, Roeske WR,
Yamamura HI: Morphine promotes phosphorylation of the human delta-
opioid receptor at serine 363. Eur J Pharmacol 2005, 519(3):212-214.
Nagi and Piñeyro Molecular Brain 2011, 4:25
http://www.molecularbrain.com/content/4/1/25
Page 7 of 937. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT:
Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science
1999, 286(5449):2495-2498.
38. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS: Relative opioid
efficacy is determined by the complements of the g protein-coupled
receptor desensitization machinery. Mol Pharmacol 2004, 66(1):106-112.
39. Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N,
Beyer A, Grecksch G, Hollt V: Receptor endocytosis counteracts the
development of opioid tolerance. Mol Pharmacol 2005, 67(1):280-287.
40. Marie N, Landemore G, Debout C, Jauzac P, Allouche S: Pharmacological
characterization of ar-m1000390 at human delta opioid receptors. Life
Sci 2003, 73(13):1691-1704.
41. Lecoq I, Marie N, Jauzac P, Allouche S: Different regulation of human
delta-opioid receptors by snc-80 [(+)-4-[(alphar)-alpha-((2s,5r)-4-allyl-
2,5-dimethyl-1-piperazinyl)-3-meth oxybenzyl]-n, n-diethylbenzamide]
and endogenous enkephalins. J Pharmacol Exp Ther 2004,
310(2):666-677.
42. Gomes BA, Shen J, Stafford K, Patel M, Yoburn BC: Mu-opioid receptor
down-regulation and tolerance are not equally dependent upon
g-protein signaling. Pharmacol Biochem Behav 2002, 72(1-2):273-278.
43. Law PY, Erickson LJ, El-Kouhen R, Dicker L, Solberg J, Wang W, Miller E,
Burd AL, Loh HH: Receptor density and recycling affect the rate of
agonist-induced desensitization of mu-opioid receptor. Mol Pharmacol
2000, 58(2):388-398.
44. Trapaidze N, Gomes I, Bansinath M, Devi LA: Recycling and resensitization
of delta opioid receptors. DNA Cell Biol 2000, 19(4):195-204.
45. Hasbi A, Allouche S, Sichel F, Stanasila L, Massotte D, Landemore G,
Polastron J, Jauzac P: Internalization and recycling of delta-opioid
receptor are dependent on a phosphorylation-dephosphorylation
mechanism. J Pharmacol Exp Ther 2000, 293(1):237-247.
46. Archer-Lahlou E, Audet N, Amraei MG, Huard K, Paquin-Gobeil M, Pineyro G:
Src promotes delta opioid receptor (dor) desensitization by interfering
with receptor recycling. J Cell Mol Med 2009, 13(1):147-163.
47. Whistler JL, Enquist J, Marley A, Fong J, Gladher F, Tsuruda P, Murray SR,
Von Zastrow M: Modulation of postendocytic sorting of g protein-
coupled receptors. Science 2002, 297(5581):615-620.
48. Hislop JN, Henry AG, Marchese A, von Zastrow M: Ubiquitination regulates
proteolytic processing of g protein-coupled receptors after their sorting
to lysosomes. J Biol Chem 2009, 284(29):19361-19370.
49. Marchese A, Paing MM, Temple BR, Trejo J: G protein-coupled receptor
sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol 2008,
48:601-629.
50. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J,
Li ZY, Wang Q, et al: Facilitation of mu-opioid receptor activity by
preventing delta-opioid receptor-mediated codegradation. Neuron 2011,
69(1):120-131.
51. Chaturvedi K, Bandari P, Chinen N, Howells RD: Proteasome involvement
in agonist-induced down-regulation of mu and delta opioid receptors. J
Biol Chem 2001, 276(15):12345-12355.
52. Tsao PI, von Zastrow M: Type-specific sorting of g protein-coupled
receptors after endocytosis. J Biol Chem 2000, 275(15):11130-11140.
53. Ko JL, Arvidsson U, Williams FG, Law PY, Elde R, Loh HH: Visualization of
time-dependent redistribution of delta-opioid receptors in neuronal cells
during prolonged agonist exposure. Brain Res Mol Brain Res 1999,
69(2):171-185.
54. Henry AG, White IJ, Marsh M, von Zastrow M, Hislop JN: The role of
ubiquitination in lysosomal trafficking of delta-opioid receptors. Traffic
2011, 12(2):170-184.
55. Heydorn A, Sondergaard BP, Ersboll B, Holst B, Nielsen FC, Haft CR,
Whistler J, Schwartz TW: A library of 7tm receptor c-terminal tails.
Interactions with the proposed post-endocytic sorting proteins erm-
binding phosphoprotein 50 (ebp50), n-ethylmaleimide-sensitive factor
(nsf), sorting nexin 1 (snx1), and g protein-coupled receptor-associated
sorting protein (gasp). J Biol Chem 2004, 279(52):54291-54303.
56. Tanowitz M, von Zastrow M: A novel endocytic recycling signal that
distinguishes the membrane trafficking of naturally occurring opioid
receptors. J Biol Chem 2003, 278(46):45978-45986.
57. Koch T, Schulz S, Schroder H, Wolf R, Raulf E, Hollt V: Carboxyl-terminal
splicing of the rat mu opioid receptor modulates agonist-mediated
internalization and receptor resensitization. J Biol Chem 1998,
273(22):13652-13657.
58. Koch T, Schulz S, Pfeiffer M, Klutzny M, Schroder H, Kahl E, Hollt V: C-
terminal splice variants of the mouse mu-opioid receptor differ in
morphine-induced internalization and receptor resensitization. J Biol
Chem 2001, 276(33):31408-31414.
59. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, Schroder H, Hollt V:
Membrane glycoprotein m6a interacts with the micro-opioid receptor
and facilitates receptor endocytosis and recycling. J Biol Chem 2007,
282(30):22239-22247.
60. Wang F, Chen X, Zhang X, Ma L: Phosphorylation state of mu-opioid
receptor determines the alternative recycling of receptor via rab4 or
rab11 pathway. Mol Endocrinol 2008, 22(8):1881-1892.
61. Zhang X, Wang F, Chen X, Chen Y, Ma L: Post-endocytic fates of delta-
opioid receptor are regulated by grk2-mediated receptor
phosphorylation and distinct beta-arrestin isoforms. J Neurochem 2008,
106(2):781-792.
62. Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT:
Differential activation and trafficking of micro-opioid receptors in brain
slices. Mol Pharmacol 2008, 74(4):972-979.
63. Minnis JG, Patierno S, Kohlmeier SE, Brecha NC, Tonini M, Sternini C:
Ligand-induced mu opioid receptor endocytosis and recycling in enteric
neurons. Neuroscience 2003, 119(1):33-42.
64. Patierno S, Anselmi L, Jaramillo I, Scott D, Garcia R, Sternini C: Morphine
induces mu opioid receptor endocytosis in guinea pig enteric neurons
following prolonged receptor activation. Gastroenterology 2011,
140(2):618-626.
65. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M: Neurokinin
1 receptors regulate morphine-induced endocytosis and
desensitization of mu-opioid receptors in cns neurons. J Neurosci 2009,
29(1):222-233.
66. Walwyn W, Evans CJ, Hales TG: Beta-arrestin2 and c-src regulate the
constitutive activity and recycling of mu opioid receptors in dorsal root
ganglion neurons. J Neurosci 2007, 27(19):5092-5104.
67. Nomura K, Reuveny E, Narahashi T: Opioid inhibition and desensitization
of calcium channel currents in rat dorsal root ganglion neurons. J
Pharmacol Exp Ther 1994, 270(2):466-474.
68. Dang VC, Napier IA, Christie MJ: Two distinct mechanisms mediate acute
mu-opioid receptor desensitization in native neurons. J Neurosci 2009,
29(10):3322-3327.
69. Van Vliet BJ, De Vries TJ, Wardeh G, Mulder AH, Schoffelmeer AN: Mu-
opioid receptor-regulated adenylate cyclase activity in primary cultures
of rat striatal neurons upon chronic morphine exposure. Eur J Pharmacol
1991, 208(2):105-111.
70. Dang VC, Williams JT: Chronic morphine treatment reduces recovery
from opioid desensitization. J Neurosci 2004, 24(35):7699-7706.
71. Narita M, Kuzumaki N, Suzuki M, Oe K, Yamazaki M, Yajima Y, Suzuki T:
Increased phosphorylated-mu-opioid receptor immunoreactivity in the
mouse spinal cord following sciatic nerve ligation. Neurosci Lett 2004,
354(2):148-152.
72. Zollner C, Mousa SA, Fischer O, Rittner HL, Shaqura M, Brack A, Shakibaei M,
Binder W, Urban F, Stein C, Schafer M: Chronic morphine use does not
induce peripheral tolerance in a rat model of inflammatory pain. J Clin
Invest 2008, 118(3):1065-1073.
73. Chen W, Marvizon JC: Acute inflammation induces segmental, bilateral,
supraspinally mediated opioid release in the rat spinal cord, as
measured by mu-opioid receptor internalization. Neuroscience 2009,
161(1):157-172.
74. Trafton JA, Abbadie C, Marek K, Basbaum AI: Postsynaptic signaling via
the [mu]-opioid receptor: Responses of dorsal horn neurons to
exogenous opioids and noxious stimulation. J Neurosci 2000,
20(23):8578-8584.
75. Lao L, Song B, Chen W, Marvizon JC: Noxious mechanical stimulation
evokes the segmental release of opioid peptides that induce mu-opioid
receptor internalization in the presence of peptidase inhibitors. Brain Res
2008, 1197:85-93.
76. Liu JG, Rovnaghi CR, Garg S, Anand KJ: Opioid receptor desensitization
contributes to thermal hyperalgesia in infant rats. Eur J Pharmacol 2004,
491(2-3):127-136.
77. Kim JA, Bartlett S, He L, Nielsen CK, Chang AM, Kharazia V, Waldhoer M,
Ou CJ, Taylor S, Ferwerda M, Cado D, et al: Morphine-induced receptor
endocytosis in a novel knockin mouse reduces tolerance and
dependence. Curr Biol 2008, 18(2):129-135.
Nagi and Piñeyro Molecular Brain 2011, 4:25
http://www.molecularbrain.com/content/4/1/25
Page 8 of 978. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG: Mu-opioid
receptor desensitization by beta-arrestin-2 determines morphine
tolerance but not dependence. Nature 2000, 408(6813):720-723.
79. Bohn LM, Lefkowitz RJ, Caron MG: Differential mechanisms of morphine
antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.
J Neurosci 2002, 22(23):10494-10500.
80. Narita M, Suzuki M, Niikura K, Nakamura A, Miyatake M, Yajima Y, Suzuki T:
Mu-opioid receptor internalization-dependent and -independent
mechanisms of the development of tolerance to mu-opioid receptor
agonists: Comparison between etorphine and morphine. Neuroscience
2006, 138(2):609-619.
81. Patel MB, Patel CN, Rajashekara V, Yoburn BC: Opioid agonists differentially
regulate mu-opioid receptors and trafficking proteins in vivo. Mol
Pharmacol 2002, 62(6):1464-1470.
82. Narita M, Yoshizawa K, Aoki K, Takagi M, Miyatake M, Suzuki T: A putative
sigma1 receptor antagonist ne-100 attenuates the discriminative
stimulus effects of ketamine in rats. Addict Biol 2001, 6(4):373-376.
83. Sim LJ, Selley DE, Dworkin SI, Childers SR: Effects of chronic morphine
administration on mu opioid receptor-stimulated [35s]gtpgammas
autoradiography in rat brain. J Neurosci 1996, 16(8):2684-2692.
84. Maher CE, Martin TJ, Childers SR: Mechanisms of mu opioid receptor/g-
protein desensitization in brain by chronic heroin administration. Life Sci
2005, 77(10):1140-1154.
85. Sirohi S, Dighe SV, Walker EA, Yoburn BC: The analgesic efficacy of
fentanyl: Relationship to tolerance and mu-opioid receptor regulation.
Pharmacol Biochem Behav 2008, 91(1):115-120.
86. Beaudry H, Proteau-Gagne A, Li S, Dory Y, Chavkin C, Gendron L:
Differential noxious and motor tolerance of chronic delta opioid
receptor agonists in rodents. Neuroscience 2009, 161(2):381-391.
87. Bradbury FA, Zelnik JC, Traynor JR: G protein independent
phosphorylation and internalization of the delta-opioid receptor.
J Neurochem 2009, 109(5):1526-1535.
88. Marie N, Lecoq I, Jauzac P, Allouche S: Differential sorting of human delta-
opioid receptors after internalization by peptide and alkaloid agonists.
J Biol Chem 2003, 278(25):22795-22804.
89. Audet N, Paquin-Gobeil M, Landry-Paquet O, Schiller PW, Pineyro G:
Internalization and src activity regulate the time course of erk activation
by delta opioid receptor ligands. J Biol Chem 2005, 280(9):7808-7816.
90. Hong MH, Xu C, Wang YJ, Ji JL, Tao YM, Xu XJ, Chen J, Xie X, Chi ZQ,
Liu JG: Role of src in ligand-specific regulation of delta-opioid receptor
desensitization and internalization. J Neurochem 2009, 108(1):102-114.
91. Jutkiewicz EM, Kaminsky ST, Rice KC, Traynor JR, Woods JH: Differential
behavioral tolerance to the delta-opioid agonist snc80 ([(+)-4-[(alphar)-
alpha-[(2s,5r)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl ]-(3-
methoxyphenyl)methyl]-n, n-diethylbenzamide) in sprague-dawley rats.
J Pharmacol Exp Ther 2005, 315(1):414-422.
92. Gales C, Rebois RV, Hogue M, Trieu P, Breit A, Hebert TE, Bouvier M: Real-
time monitoring of receptor and g-protein interactions in living cells.
Nat Methods 2005, 2(3):177-184.
93. Dupre DJ, Hebert TE: Biosynthesis and trafficking of seven
transmembrane receptor signalling complexes. Cell Signal 2006,
18(10):1549-1559.
94. Kreienkamp HJ: Organisation of g-protein-coupled receptor signalling
complexes by scaffolding proteins. Curr Opin Pharmacol 2002,
2(5):581-586.
95. Ostrom RS, Insel PA: The evolving role of lipid rafts and caveolae in g
protein-coupled receptor signaling: Implications for molecular
pharmacology. Br J Pharmacol 2004, 143(2):235-245.
96. Pineyro G: Membrane signalling complexes: Implications for
development of functionally selective ligands modulating heptahelical
receptor signalling. Cell Signal 2009, 21(2):179-185.
doi:10.1186/1756-6606-4-25
Cite this article as: Nagi and Piñeyro: Regulation of opioid receptor
signalling: Implications for the development of analgesic tolerance.
Molecular Brain 2011 4:25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nagi and Piñeyro Molecular Brain 2011, 4:25
http://www.molecularbrain.com/content/4/1/25
Page 9 of 9